MMP9 and lung carcinoma: Overall, the results of this study shed light on the potential mechanisms underlying the additive inhibitory effect of the combination treatment of sorafenib and 5-MTP on LLC cell migration and metastasis, and emphasize the significance of vimentin and MMP9 as potential therapeutic targets in the context of lung cancer metastasis.